Erratum to: Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis (Diabetes Ther, 10.1007/s13300-015-0119-x);Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis

Diabetes Therapy

Volumn 6, Issue 3, 2015, Pages 317-328

  Fu, Haoda ^a   Cao, Dachuang ^a   Boye, Kristina S ^a   Curtis, Bradley ^a   Schuster, Dara L ^a   Kendall, David M ^a   Ascher Svanum, Haya ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Early response; Glycemic control; Gradient boosting; Insulin glargine; Metformin; Predictive values; Sulfonylurea; Type 2 diabetes

Indexed keywords

GLICLAZIDE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

ADULT; ARTICLE; CORRELATION COEFFICIENT; FEMALE; GLYCEMIC CONTROL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY;

EID: 84942314414     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-015-0132-0     Document Type: Erratum

References (38)

1. International Diabetes Foundation (2013) IDF Diabetes Atlas. 6th ed. http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Accessed Mar 2015.
2. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in US diabetes care, 1999–2010. N Engl J Med. 2013;368:1613–24.
3. Bloomgarden ZT. Achieving glycemic goals in type 2 diabetes. Diabetes Care. 2007;30:174–80.
4. Steinberg BA, Bhatt DL, Mehta S, et al. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008;156:719–27.
5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.
6. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60:1228–35.
7. Chen L, Ascher-Svanum H, Stauffer V, Kinon BJ, Kollack-Walker S, Ruberg S. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods. Schizophr Res. 2009;113:34–40.
8. Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008;102:230–40. doi:10.1016/j.schres.2008.02.021.
9. Kishi T, Matsuda Y, Fujita K, Iwata N. Early prediction of blonanserin response in Japanese patients with schizophrenia. Neuropsychiatr Dis Treat. 2014;10:1861–6.
10. Ruberg SJ, Chen L, Stauffer V, et al. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry. 2011;11:23.
11. Kemp DE, Ganocy SJ, Brecher M, et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord. 2011;130:171–9.
12. Vermeiden M, Kamperman AM, Vulink ME, van den Broek WW, Birkenhäger TK. Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients. Psychopharmacology (Berl). 2015;232(8):1347–56. doi:10.1007/s00213-014-3765-1.
13. Block SL, Williams D, Donnelly CL, Dunn DW, Saylor KE, Ruberg SJ. Post hoc analysis: early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patients. Clin Pediatr (Phila). 2010;49:768–76.
14. Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry. 2009;48:511–8.
15. Zhu B, Edson-Heredia E, Cameron GS, et al. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2013;169:1337–41.
16. Baker JF, Ostergaard M, Emery P, et al. Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial. Ann Rheum Dis. 2014;73(11):1968–74.
17. Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366–72.
18. Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008;34:1163–71.
19. Gavin JR 3rd, Bohannon NJ. A review of the response to oral antidiabetes agents in patients with type 2 diabetes. Postgrad Med. 2010;122:43–51.
20. Hanefeld M, Bramlage P. Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial. Curr Diab Rep. 2013;13:342–9.
21. Owens DR. Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. Diabetes Technol Ther. 2013;15:776–85.
22. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001;285:182–9.
23. Karl D, Zhou R, Vlajnic A, Riddle M. Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis. Diabet Med. 2012;29:933–6.
24. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, Quartet [corrected] Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004;89:6068–76.
25. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med. 2004;22:399–405.
26. Buse JB, Wolffenbuttel BH, Herman WH, et al. The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine. Diabetes Care. 2011;34:249–55. doi:10.2337/dc10-1701.
27. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.
28. National Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice at NICE, National Institute for Health and Clinical Excellence, National Health Service. NICE clinical guideline 87. Type 2 diabetes: the management of type 2 diabetes. 2009. http://www.nice.org.uk/guidance/ta203/resources/nice-recommends-liraglutide-for-type-2-diabetes-mellitus4. Accessed Nov 2014.
29. National Institute for Health and Care Excellence. NICE technology appraisal guidance 203. Liraglutide for the treatment of type 2 diabetes mellitus. 2010. http://www.nice.org.uk/guidance/ta203/resources/guidance-liraglutide-for-the-treatment-of-type-2-diabetes-mellitus-pdf. Accessed November 2014.
30. American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34(suppl 1):S11–61.
31. Friedman JH. Stochastic gradient boosting. Comput Stat Data Anal. 2002;38:367–78.
32. Shao J. Mathematical statistics, 2nd edn, Springer texts in statistics. New York: Springer; 2003.
33. Banerji MA, Dunn JD. Impact of glycemic control on healthcare resource utilization and costs of type 2 diabetes: current and future pharmacologic approaches to improving outcomes. Am Health Drug Benefits. 2013;6(7):382–92.
34. Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab. 2012;14(3):228–33.
35. Nichols GA, Kimes TM, Harp JB, Kou TD, Brodovicz KG. Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes. Diabetes Care. 2012;35:495–7.
36. Committee on Quality of Health Care in America, Institute of Medicine. Crossing the quality chasm: A new health system for the 21st century. Washington, DC: National Academies Press; 2001.
37. Hastie T, Tibshirani R, Friedman J. The elements of statistical learning. 2nd ed. New York: Springer; 2009.
38. Office of Surveillance and Biometrics, Division of Biostatistics, Diagnostic Devices Branch, Center for Devices and Radiological Health, Food and Drug Administration, US Department of Health and Human Services. Guidance for Industry and FDA Staff: Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests. Published March 13, 2007. Washington, DC: Office of Surveillance and Biometrics, Division of Biostatistics, Diagnostic Devices Branch, Center for Devices and Radiological Health, Food and Drug Administration, US Dept of Health and Human Services; March 13, 2007.